|Dr. Elisabet de los Pinos Ph.D.||Founder, CEO, Pres & Director||676.62k||N/A||1974|
|Ms. Julie B. Feder||CFO, Sec. & Treasurer||505.45k||N/A||1970|
|Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA||Chief Medical Officer and Head of R&D||564.22k||N/A||1965|
|Dr. Mark A. De Rosch Ph.D.||Chief Operating Officer||N/A||N/A||1964|
|Mr. Paulo Carvalho||VP of Technical Operations||N/A||N/A||N/A|
|Mr. Joseph Lyons||VP of HR||N/A||N/A||N/A|
|Ms. Michele Keough M.B.A.||Sr. VP of Project Management and Device Supply Chain||N/A||N/A||N/A|
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 9.